Arcturus Therapeutics (ARCT) COVID Vaccine News 'Encouraging' - Laidlaw

Laidlaw analyst Yale Jen reiterated a Buy rating and $152.00 price target on Arcturus Therapeutics (NASDAQ: ARCT) after the company reported encouraging preliminary results from ARCT-154 and ARCT-165 Covid-19 vaccine Phase I/II study as a booster shot following the initial dose of Pfizer/BioNTech's Comirnaty.

The analyst commented, "We view this morning's news encouraging as the two vaccines potentially could have broader usage as a booster shot for other approved and marketed vaccines. Although the Covid-19 vaccination rates in many
developing countries have increased continuously, many people might still only have received the initial shot but not the complete vaccination due to logistic or supplying issues. In addition, vaccination by two different vaccines has been a more common practice in many countries. In some cases, this is even more welcomed as some publications have suggested that the potential efficacy sometimes is better than receiving the same vaccine for the initial and booster shots. As such, we believe ARCT-154 and ARCT-165 could potentially fulfill the need in those situations. Further, although the results of initial ARCT-154 Phase I and II study in Vietnam are not yet available, the nAbs increases demonstrated from the booster study reported today could strongly suggest that this vaccine could be very effective in human."

For an analyst ratings summary and ratings history on Arcturus Therapeutics click here. For more ratings news on Arcturus Therapeutics click here.

Shares of Arcturus Therapeutics closed at $35.52 yesterday.

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat